Phase I trial of BB-10901 (huN901-DM1) given daily by IV infusion for three consecutive days every three weeks in patients with SCLC and other CD56-positive solid tumors

P Lorigan; P Woll; M O'Brien; Y Clinch; K Donaldson; HS Xie; P Wunderli; J Hutchison; RJ Fram

Phase I trial of BB-10901 (huN901-DM1) given daily by IV infusion for three consecutive days every three weeks in patients with SCLC and other CD56-positive solid tumors

P Lorigan, P Woll, M O'Brien, Y Clinch, K Donaldson, HS Xie, P Wunderli, J Hutchison, RJ Fram

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	9055S-9055S
Number of pages	1
Journal	Clinical Cancer Research
Volume	11
Issue number	24 (part 2)
Publication status	Published - 15 Dec 2005
Event	AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications - Philadelphia, United States Duration: 14 Nov 2005 → 18 Nov 2005 https://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=184

Cite this

@article{68f60cd953e645a1ba546cfd9411fd1f,

title = "Phase I trial of BB-10901 (huN901-DM1) given daily by IV infusion for three consecutive days every three weeks in patients with SCLC and other CD56-positive solid tumors",

author = "P Lorigan and P Woll and M O'Brien and Y Clinch and K Donaldson and HS Xie and P Wunderli and J Hutchison and RJ Fram",

year = "2005",

month = dec,

day = "15",

language = "English",

volume = "11",

pages = "9055S--9055S",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research",

number = "24 (part 2)",

note = "AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics : Discovery, Biology, and Clinical Applications ; Conference date: 14-11-2005 Through 18-11-2005",

url = "https://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=184",

}

Phase I trial of BB-10901 (huN901-DM1) given daily by IV infusion for three consecutive days every three weeks in patients with SCLC and other CD56-positive solid tumors. / Lorigan, P; Woll, P; O'Brien, M et al.
In: Clinical Cancer Research, Vol. 11, No. 24 (part 2), 15.12.2005, p. 9055S-9055S.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Phase I trial of BB-10901 (huN901-DM1) given daily by IV infusion for three consecutive days every three weeks in patients with SCLC and other CD56-positive solid tumors

AU - Lorigan, P

AU - Woll, P

AU - O'Brien, M

AU - Clinch, Y

AU - Donaldson, K

AU - Xie, HS

AU - Wunderli, P

AU - Hutchison, J

AU - Fram, RJ

PY - 2005/12/15

Y1 - 2005/12/15

UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000234382700370&KeyUID=WOS:000234382700370

M3 - Meeting Abstract

SN - 1078-0432

VL - 11

SP - 9055S-9055S

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 24 (part 2)

T2 - AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Y2 - 14 November 2005 through 18 November 2005

ER -

Phase I trial of BB-10901 (huN901-DM1) given daily by IV infusion for three consecutive days every three weeks in patients with SCLC and other CD56-positive solid tumors

Other files and links

Cite this